Table 3 Base case results
Non-prophylaxis | Palivizumab | Incremental palivizumab vs non-prophylaxis. | |
|---|---|---|---|
QALYs | 5.19 | 5.26 | 0.0731 |
COSTS | |||
Total costs | €671.68 | €2,110.71 | €1,439.03 |
Prophylaxis costs (pharmaceutical and administration) | €0.00 | €1,886.78 | €1,886.78 |
Hospital related costs | €246.44 | €78.14 | €-168.30 |
Recurrent wheezing management costs | €425.23 | €145.78 | €-279.45 |
ICUR (€/QALY gained with palivizumab vs non-prophylaxis | 1,9697.69 | ||